Financial Performance - IT Services revenue reached $2,587.4 million in Q1'26 [26] - IT Services revenue decreased by 0.3% QoQ and 1.5% YoY in reported terms [26] - Non-GAAP IT Services revenue decreased by 2.0% QoQ and 2.3% YoY in constant currency terms [26] - Net income for the quarter was ₹33.3 billion, a decrease of 6.7% QoQ and an increase of 10.9% YoY [26] - EPS was ₹3.2 ($0.041), a decrease of 6.7% QoQ and an increase of 10.8% YoY [26] - IT Services Operating Margins was at 17.3%, down by 0.2% QoQ and expansion of 0.8% YoY [26] Bookings and Deals - Total bookings were $4,971 million, up by 24.1% QoQ and 50.7% YoY in constant currency [28] - Large deal bookings were $2,666 million, an increase of 49.7% QoQ and 130.8% YoY in constant currency [28] Other Key Metrics - The company has 1,282 active global clients [10] - Top customer concentration is at 4.7% of revenue [12]

Q2 2025 Performance - Adjusted EBITDA for Q2 2025 was $27.1 million[3], compared to $31.7 million in Q2 2024[3, 4], a decrease of 14.5% - The Transportation segment's Adjusted EBITDA decreased from $11.2 million in Q2 2024 to $8.5 million in Q2 2025[3, 4], a decrease of 24.1% - The Specialty Products segment's Adjusted EBITDA decreased from $5.7 million in Q2 2024 to $4.4 million in Q2 2025[3, 4], a decrease of 22.8% - The Sulfur Services segment's Adjusted EBITDA decreased from $10.6 million in Q2 2024 to $9.7 million in Q2 2025[3, 4], a decrease of 8.5% - The Terminalling & Storage segment's Adjusted EBITDA increased from $8.0 million in Q2 2024 to $8.4 million in Q2 2025[3, 4], an increase of 5% Full-Year 2025 Guidance - The company projects a full-year 2025 Adjusted EBITDA of $109.1 million[5] - Total segment adjusted EBITDA is projected to be $123.8 million[5] - Maintenance capital expenditures are estimated at $20.5 million, and plant turnaround costs at $5.4 million[5] - Total distributable cash flow is projected to be $27.8 million[5] - Total adjusted free cash flow is projected to be $18.8 million[5]

Financial Performance - Abbott's worldwide sales reached $11.1 billion, reflecting a 7.5% increase[3] - Organic sales growth, excluding foreign exchange and the discontinued ZonePerfect product line, showed a growth between 7.5% to 8.0%[3, 6] - Adjusted diluted EPS was $1.26 for the quarter[4] - Full-year 2025 guidance for adjusted diluted EPS is projected to be between $5.10 and $5.20[5] Business Unit Performance - Medical Devices sales amounted to $5.4 billion[4] - Diagnostics sales reached $2.2 billion[4] - Established Pharmaceuticals sales were $1.4 billion[4] Strategic Highlights - The company is expanding its structural heart portfolio[4] - The company is pioneering leadless cardiac pacing[5] - The company is advancing heart rhythm management[7] - FDA approved Abbott's Tendyne™ transcatheter mitral valve replacement (TMVR) system[11] - The AVEIR™ Conduction System Pacing clinical feasibility study is evaluating a leadless pacemaker delivering conduction pacing[12]

Financial Performance - Fifth Third Bancorp's adjusted PPNR achieved its highest growth rate in 2 years[8] - The adjusted efficiency ratio improved by 130 bps[8] to 55.5%[9, 21] - Adjusted EPS was $0.90[9, 175] - Return on average tangible common equity was 18%[9] - Net interest income increased to $1.5 billion[13] Loan and Deposit Trends - Average consumer loans increased by 7% compared to 2Q24[10] - Average commercial loans increased by 4% compared to 2Q24[10] - Consumer household growth was 2% compared to 2Q24, with 6% growth in the southeast[10] - Non-interest bearing deposits represent 25.3% of total deposits[35] Credit Quality - Non-performing assets decreased by 11% sequentially[8] - Commercial non-performing assets declined by 18%[8] - Net charge-off ratio was 0.45%[37] Outlook - Average loans & leases are expected to increase by approximately 5% for FY2025 compared to FY2024[54] - Net interest income is projected to increase by 5.5% - 6.5% for FY2025 compared to FY2024[54]

Financial Performance - Reported PPNR was $370.1 million[4] - Net income applicable to common shareholders was $251.7 million[4] - Diluted EPS reached $1.52[4] - ROAA stood at 1.29%[4, 5] - ROATCE was 17.96%[4, 5] Balance Sheet Highlights - Loans increased by $0.6 billion, a 1.2% LQ increase[5] - Excluding loans moved to held for sale, loan growth would have been $0.9 billion, or 1.6%[5, 14] - Total deposits grew by $0.7 billion, representing a 1.1% LQ increase[5] - TBVPS grew 3.4% to $35.13 LQ[5] - Total loans as a % of earning assets is 73%[83] Key Ratios - The loan-to-deposit ratio was 80.9%[5, 7] - The efficiency ratio improved to 45.4%, down 0.4% LQ[5] - CET1 was 11.33%[5, 7] - TCE was 7.46%[5, 7] Loan Portfolio - Total loans reached $53.672 billion[7] - Commercial loans totaled $42.652 billion[7] - Consumer loans amounted to $11.020 billion[7] - C&I loans increased by $420 million LQ, or 3.0%, reaching $14.232 billion[11] - CRE decreased by $44 million LQ, or -0.2%, reaching $21.111 billion[11] Deposit Portfolio - Total deposits reached $66.314 billion[7] - Transactional deposits totaled $19.164 billion[7] - Healthcare Financial Services deposits were $10.180 billion[7] - interSYNC deposits were $8.719 billion[16] - Ametros accounts were $1.115 billion[16] Net Interest Income and Margin - Net interest income totaled $621.2 million, up $9.0 million or 1.5% LQ[21, 26] - Net interest margin was 3.44%, down 4 bps LQ[5, 21] Commercial Real Estate Portfolio - The commercial real estate portfolio totaled $18.8 billion[57, 61] - Classified loans were 3.9%[57]

Financial Performance Highlights - Net interest income increased by $174 million QoQ, supported by continued LHI growth and further reduction in funding costs[35] - Net interest margin expanded by 16 bps QoQ, and 34 bps YoY[35] - Adjusted non-interest expense increased $09 million YoY to $1889 million, reflecting continued repositioning of the expense base in support of defined growth objectives[35] - The company sold $2823 million of available for sale securities with a book yield of 31% in the quarter for a pre-tax loss of $19 million[28] Balance Sheet and Capital Position - Total assets reached $31944 billion, a 7% increase YoY[9] - Total deposits reached $26064 billion[9] - Tangible book value per share increased by $217 or 3% QoQ to $7014 as a result of income generated, share repurchase activity and AOCI accretion[57] - The company repurchased 318 thousand shares in Q2, 07% of year end 2024 shares outstanding, for a total of $21 million at a weighted average price of approximately 96% of prior month tangible book value per share[57] Asset Quality - Total ACL increased $20 million QoQ to $3343 million[44] - Criticized LHI declined $2222 million or 26% YoY, with the percentage of total LHI declining 129 bps to 266%[45] - Special mention LHI declined $1443 million or 30% linked quarter[45] Strategic Performance and Guidance - Full year 2024 adjusted total revenue was $1119 million[58] - The company expects mid to high single-digit percent growth for adjusted non-interest expense[58] - The company expects provisions / average LHI, excl mortgage finance LHI to be 30 bps - 35 bps[58] - The company expects CET1 Ratio to be greater than 11%[58]

Second Quarter Results July 17, 2025 FORWARD-LOOKING STATEMENT This presentation contains statements, including statements regarding economic and geopolitical uncertainty, including uncertainty regarding trade policy developments, trends in labor demand and the future strengthening of such demand, the impact of AI on labor markets, financial outlook, outlook for our business in the regions in which we operate as well as key countries within those regions, the Company's strategic initiatives and technology i ...

Financial Performance - Net interest income increased by 1% QoQ to $459561 thousand[7] and 6% YoY[7] - Non-interest revenue increased significantly by 15% QoQ and 204% YoY to $134135 thousand[7] - Total revenue grew by 4% QoQ and 94% YoY reaching $593696 thousand[7] - Adjusted diluted EPS increased by 14% QoQ and 28% YoY to $148[7] - Adjusted revenue is expected to be between $495 million and $515 million for 2025[38] Balance Sheet - Loans increased by 2% QoQ to $43537 million[9] and 1% YoY[9] - Deposits decreased by 2% QoQ to $49925 million[9] and 1% YoY[9] - Core deposits decreased by 2% QoQ but increased by 1% YoY, reaching $45208 million[9] - Non-interest bearing deposits remained relatively stable at $11658 million[9] Credit Quality & Capital - The net charge-off ratio improved to 017%[9] - The non-performing loan ratio remained stable at 059%[9] - The CET1 ratio increased to 1091%[9]

Financial Performance - Elevance Health's operating revenue for 2Q 2025 grew by 143% to $494 billion [7, 9] - The medical loss ratio was 889% [9] - Adjusted operating expense ratio improved by 140 bps to 100% [9] - Operating cash flow was $21 billion [9] - Adjusted diluted earnings per share (EPS) decreased by 142% to $884 [7] Segment Results - Health Benefits operating revenue increased by 119% to $416 billion [11] - Health Benefits adjusted operating margin decreased by 200 bps to 38% [12] - Carelon revenue increased by 358% to $181 billion [14] - CarelonRx revenue increased by 213% to $1064 billion [33] - Carelon Services revenue increased by 637% to $7441 billion [33] Strategic Focus - Elevance Health is focused on simplifying healthcare, affordability, and accessibility for consumers [3, 5] - The company aims to deepen clinical and business partnerships with care providers [4, 5] - Elevance Health is targeting at least 12% average annual growth in Adjusted Diluted Earnings Per Share [19, 20]

Q2 2025 Financial Performance - Novartis delivered double-digit sales growth and core margin expansion in Q2 2025 [134] - Q2 sales reached USD 141 billion, an increase of 11% in constant currencies (cc) compared to Q2 2024 [14] - Core operating income for Q2 2025 was USD 59 billion, a 21% increase in constant currencies (cc) compared to Q2 2024 [14] - Core margin improved to 422%, a 340 basis points increase [14] - Free cash flow for H1 2025 increased by 46% to USD 97 billion [104] FY 2025 Guidance and Capital Allocation - FY 2025 core operating income guidance upgraded to low-teens growth from low double-digit [15] - A new share buyback program of up to USD 10 billion was initiated, to be completed by the end of 2027 [108] - The company assumes Entresto US generic entry in mid-2025 for forecasting purposes [112] Key Products Performance - Kisqali grew by 64% cc in Q2, achieving TRx leadership in mBC [23] - Kesimpta grew by 33% cc in Q2, driven by strong demand growth [31] - Pluvicto grew by 30% cc in Q2, with promising uptake since pre-taxane indication approval in the US [36] - Leqvio grew by 61% cc in Q2, on track for blockbuster status in 2025 [45] - Scemblix grew by 79% cc in Q2, with strong momentum in early lines and global leadership in 3L+ CML [52]